TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01409993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 25 mg by mouth three times a day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 25 mg by mouth three times a day for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times a day for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times a day for three months

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycemic clamp
Description: Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp
Description: Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Euglycemic clamp
Description: Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp
Description: Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
Study: NCT00977015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Inhaled, 750/150, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Inhaled, 750/150, single dose
Study: NCT01644955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
Study: NCT03908710

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment of hypertension using blood pressure self-measurement at home
Description: The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
Study: NCT02052934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
Study: NCT03182465

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Value of ProCalcitonin
Description: The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
Study: NCT02199613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment simplification
Description: Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
Study: NCT01338883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 100 mg
Description: 100 mg CVC plus Truvada

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 200 mg + Truvada
Description: 200 mg CVC plus Truvada

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustiva + Truvada
Description: Sustiva plus Truvada
Study: NCT04090047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
Study: NCT02949011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Tablets taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: Matching tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: Matching tablets taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Capsules taken orally
Study: NCT02819141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
Study: NCT02560441

Intervention type: OTHER
Group type: OTHER
Intervention: chemotherapy followed by radiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: radiotherapy followed by chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: IPGDP regimen chemotherapy
Study: NCT01991665

Intervention type: OTHER
Group type: OTHER
Intervention: Digital examination

Intervention type: OTHER
Group type: OTHER
Intervention: Digital examination
Study: NCT02949011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Oseltamivir
Description: Matching placebo capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Oseltamivir
Description: Matching placebo capsules taken orally
Study: NCT04046640

Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.

Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.
Study: NCT01991665

Intervention type: OTHER
Group type: OTHER
Intervention: Sonography evaluation
Study: NCT00825136

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation
Description: Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback (finger temperature biofeedback)
Description: Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
Study: NCT03659474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression
Description: compression by Game Ready

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice pack
Description: cryotherapy for ice pack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: immersion therapy
Study: NCT02053675

Intervention type: DRUG
Group type: OTHER
Intervention: Vasopressin infusion
Study: NCT02980874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprachoroidal CLS-TA
Description: suprachoroidal injection of CLS-TA
Study: NCT04874467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy
Description: A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy
Description: A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit.
Study: NCT01546844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in Care4Life
Description: Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
Study: NCT03737292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
Study: NCT01710969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual intervention
Description: 34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: 34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
Study: NCT00144391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Testosterone gel
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Testosterone gel
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
Study: NCT02034968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab: 200mg,IV once a week during chemotherapy.
Study: NCT02685189

Intervention type: OTHER
Intervention: Previous exposure to stannsoporfin
Description: No intervention in this protocol
Study: NCT01025258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequent Scheduled CF clinic visits
Description: Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
Study: NCT03376152

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric Kettle Promotion
Description: Provision of free electric kettles and promotional materials/information
Study: NCT03882502

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation
Description: anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation
Description: anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
Study: NCT01025258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: frequent telephone calls to patients pre and post visits to the clinic
Description: Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
Study: NCT00635674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP device - REMstar Plus, Respironics, Murrysville, USA
Description: continuous positive airway pressure device with heated humidification

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device - REMstar Plus, Respironics, Murrysville, USA
Description: continuous positive airway pressure device with heated humidification
Study: NCT00730769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single arm (ganciclovir and valganciclovir)
Description: Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
Study: NCT01211470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Active Comparator: Daptomycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMX-30063-investigational drug
Description: Experimental: PMX-30063
Study: NCT02758990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Subjects will be asked to increase vitamin B6 intake by 50 mg per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Subjects will be asked to increase vitamin C intake by 500 mg per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Subjects will be asked to increase vitamin C intake by 500 mg per day.
Study: NCT01541371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
Study: NCT02758990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
Study: NCT04567524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LYN-005
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LYN-005
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Study: NCT05233514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in addition to Metformin treatment
Description: The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise in addition to Metformin treatment
Description: The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
Study: NCT03071965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Description: The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Description: The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to implant device for NT-501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to implant device for NT-501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Sham surgery
Study: NCT04274595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic antiretroviral
Description: 200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days